

An Introduction to Anemia and Bilirubinemia

Ankita Dey, Gladimir V.G. Baranoski and Tenn F. Chen
Natural Phenomena Simulation Group, School of Computer Science, University of Waterloo

Technical Report CS-2014-17

November 7, 2014

1 Introduction

In this report, we provide an overview of two serious medical conditions, anemia and bilirubinemia (commonly known as jaundice), which are associated with changes in the contents of specific chromophores present in the blood stream. In general terms, anemia results from a decrease in the hemoglobin content, while jaundice results from an increase in the bilirubin content. Both of them have a significant impact on public health worldwide, with anemia being more prevalent among women of childbearing age, and jaundice more common among neonates due their underdeveloped liver.

In the remainder of this report, we briefly address their causes, types, symptoms and treatment options. In Section 2, we examine these points with respect to anemia, and in Section 3 with respect to jaundice. This report closes with a summary and general observations about these two medical conditions.

2 Anemia

Anemia is a condition that arises due to a decrease in the number of hemoglobin-containing red blood cells (RBCs). Hemoglobin is an iron-containing transport protein that carries oxygen in the blood stream from respiratory organs (lungs) to the rest of the body [1]. Besides the depletion of RBCs, anemia can also result from a decrease in the oxygen-binding ability of hemoglobin molecules [2]. In this case, there may or may not be normal hemoglobin concentration in the blood. According to Chang *et al.* [3], the depletion of RBCs can result from a number of pathologies and risky situations:

- ulcers;
- cancer;
- faulty bone marrow¹;
- infections (malaria in rural areas [5]);
- menstruation;
- surgery;

¹RBCs are produced in the bone marrow. Anemia can result from a serious bone marrow disorder, which is more commonly caused by a lack of vitamin B_{12} [4].

- medications or antibiotics (which may cause delays in immune reactions); and
- malnutrition.

The most common form of anemia is the iron deficiency anemia (IDA) which is caused by the premature or excessive destruction of red blood cells before they can be properly repleted [4]. It is worth noting that iron deficiency may not always lead to anemic conditions [6] and the average hemoglobin concentration for healthy individuals differs across race, gender and age. For example, amongst adult individuals characterized by darkly pigmented skin, the average concentration is 8 *g/l* lower than that of other ethnic groups [6]. Almost all studies about anemia consider four focus groups: infants, children, non-pregnant women and pregnant women. Table 1 provides lower bound values for hemoglobin concentration and hematocrit² in nonanemic individuals belonging to these groups.

Group	Hemoglobin (<i>g/l</i>)	Hematocrit (%)
infants	110	33
children	115	35
women (non-pregnant)	120	36
women (pregnant)	110	33

Table 1: Lower bound values for hemoglobin concentration in nonanemic individuals [6].

Another form of anemia, known as pernicious anemia, occurs as a result of vitamin B_{12} deficiency in the liver [8, 9]. It usually occurs when IDA is already in place, and it is often detected at a later stage when the iron deficiency is well established. Once it is detected, it can be treated by administering vitamin B_{12} . Pernicious anemia is most commonly found in older women [10].

Abnormal or severe below-normal hemoglobin contents associated with the onset of anemia can hamper the oxygen supply to various organs [11]. Table 2 gives an indication of what can be considered as mild, moderate and severe cases of anemia associated with these contents. Studies have shown that anemic patients have 41% higher chance of suffering a heart attack than nonanemic individuals [12]. In some cases, it may lead to death since parts of the heart are not receiving enough oxygen, and this, in turn, may cause artery blockages. In these cases, transfusions are necessary to raise hemoglobin contents to normal, and consequently reduce significant symptoms of anemia. It is worth noting that an increased degradation of hemoglobin and a consequent reduction of its content in the blood stream may also lead to bilirubinemia [13].

Severity	Hb Range (<i>g/l</i>)
mild	110 – 129
moderate	80 – 109
severe	< 80

Table 2: Hemoglobin (Hb) contents associated with different levels of anemia severity in men (15 years of age and above) [14].

²Hematocrit is the ratio of volume of RBCs to the volume of blood, and it is rounded off to the nearest percent [7].

Segment/Organ	Symptoms and Signs (mild to intermediate levels)	Additional Symptoms (severe level)
eyes	yellowness	
skin	paleness coldness yellowness	
respiratory organs	shortness of breath	
muscles	weakness	
intestine	changed stool color	
spleen	enlargement	
heart	palpitations chest pain angina heart attack	rapid heart rate
blood vessels	low blood pressure	
central nervous system	fatigue dizziness	fainting

Table 3: Symptoms and signs associated with normal to severe levels of anemia [15]. Symptom is a feeling that a person experience with a disease or conditions (*e.g.*, chest pain), while a sign is an evidence of such a disease or condition that someone else can observe or measure (*e.g.*, yellowish skin) [4].

In order to avert or mitigate the serious consequences of anemia, it is of the utmost importance to detect it in its early stages. A complete blood count (CBC) analysis or an iron content test can be conveniently used as laboratory tests to detect IDA. Apart from these, physical examinations by the medical practitioner, such as inspections of the eyes, skin or general queries about diet and anemic background in the family, can also help in diagnosing this condition [15]. Table 3 summarises anemia symptoms with respect to the different parts of the body where they are manifested [15]. In addition, anemia can lead to different types of physiological and psychological impairments whose observation can be used to complement its diagnosis [3, 16]:

- fearfulness - anemic children are more prone to being fearful and anxious;
- functional isolation - anemic children were observed to be markedly less active than nonanemic children when it came to exploring their environment and moving around;
- cognitive and developmental deficiency;
- impaired visual potential - anemic children have shown longer delay when it comes to visually evoked

potential;

- fatigue, tiredness and dizziness;
- poor concentration and malaise;
- headaches and restless leg syndrome.

According to a survey conducted by the World Health Organization (WHO) [17] in 2000, nine out of ten anemia sufferers live in developing countries, and this medical condition contributes to 20% of maternal deaths each year. However, it has been noted that cases of anemia are not just confined to developing countries. Besides malnutrition, poor eating habits can also lead to the onset of this condition [17]. Hence, awareness and the promotion of proper guidelines to deal with these nutrition issues are, therefore, central for the prevention of anemia. In infants, these efforts include promoting breastfeeding and proper complementary foods. For anemic infants, supplemental iron should be provided at regular intervals and their condition monitored for improvement. For children, periodic screenings are not required once they have been scanned as infants, unless they are prone to risky conditions such as those stated earlier. In such cases, they need to be rescreened. Non-pregnant women between 15-25 years of age must be screened at least once for anemia. If the woman has a positive result, then the clinician should rescreen every 1.5 months after providing supplements or other forms of dietary treatments. In the case of pregnant women, they should be screened during their first prenatal visit and at each subsequent trimester [6].

3 Bilirubinemia

Bilirubinemia, or jaundice, refers to the yellowish pigmentation of skin and sclera caused by the presence of excess bilirubin in the blood stream [18]. Bilirubin is formed in the body and subsequently broken down by the liver through a process composed of three stages, termed pre-hepatic, hepatic and post-hepatic [19, 20]. Jaundice can be pre-hepatic, hepatic or post-hepatic, *i.e.*, it can take place at any of these stages, which are described as follows [19, 20]:

1. Pre-hepatic (occurring prior to the liver) - The breakdown of red blood cells yields bilirubin as a byproduct. RBCs can break down either after their normal cycle completion of 120 days or as an aggravation due to anemia or genetic diseases such as Gilbert's syndrome³ and thalassemia⁴. Bilirubin is produced once the RBC cell membrane disintegrates or ruptures releasing it into the blood stream. This form of bilirubin is referred to as "free", "unconjugated" or "indirect" bilirubin.
2. Hepatic (occurring within the liver) - The unconjugated bilirubin is made conjugated (water soluble) by biochemical processes in the liver. This conjugated bilirubin is then excreted as bile from the liver.
3. Post-hepatic (post conjugation of bilirubin in the liver) - This comprises of drainage of bile in the biliary system or the bile duct.

The majority of the reported jaundice cases are for neonates. One of the main reasons why this medical condition is more prevalent among neonates is that they produce more red blood cells than adults. Since

³Gilbert's syndrome affects 3-7% of the population [21], and it is caused by a degradation in activity of the enzyme present in liver that is responsible for conjugating the insoluble bilirubin, *i.e.*, making it water soluble [22].

⁴Thalassemia is an inherited disorder where body does not produce enough hemoglobin due to the weakening and premature destruction of the RBCs [23].

a neonate’s liver is not fully developed, it may not be completely successful in removing adequate amounts of bilirubin from the body [24]. The common types of neonatal jaundice include [24]:

- “normal” jaundice - characterized by the slow processing of bilirubin by the neonate’s liver;
- prematurity jaundice - in premature neonates, jaundice occurs more frequently since their liver is even less developed; and
- breast milk jaundice/blood group incompatibility jaundice - characterized by a sudden buildup of bilirubin in the neonate’s blood either due to substances produced in the breast milk or due to a different blood type of the mother.

The bilirubin contents for neonates (as shown in Table 4) are different from that of adults [25]. In fact, it differs even from premature to full term neonates [26]. In adults, jaundice can result from the inflammation of liver caused by viruses, known as hepatitis. The most generic forms of this disease are hepatitis A, B and C [27]. Hepatitis A is transmitted through contaminated food or water. The virus is excreted in the faeces of an infected person, and thus, transmission is enhanced under poor hygiene conditions [27]. Hepatitis B is more likely to be passed at an infantile stage via exposure to infected maternal blood. In addition to this, it can be transmitted by sexual contact or ensued as a result of drug abuse [28, 29]. Hepatitis C is more likely to be transmitted through blood transfusions [30]. Although vaccines for hepatitis A and B are available, there is no vaccine for protecting against hepatitis C [30]. Jaundice can also be a consequence of obstructive cholestasis⁵, which, in turn, may result from genetic disorders such as Gilbert’s syndrome [22]. Crigler-Najjar, Dubin-Johnson and Rotors syndromes are other genetic disorders that cause abnormal secretion of bilirubin into bile, which ultimately leads to jaundice [22]. It is worth noting that jaundice is caused by a higher bilirubin content in elderly patients than in younger ones [32]. Moreover, a recent study has shown that, for patients suffering from chronic hepatitis, the bilirubin contents tend to be slightly higher in males than females [33]. In that study, groups of male and female patients suffering from chronic hepatitis were divided in the age bands of 31-40 years, 41-50 years, 51-60 years and 61-76 years, in order to allow a more detailed analysis of the variance of total bilirubin.

Age/Time	Premature	Full Term
< 24 hours	< 8.0 <i>mg/dl</i> (below 137 <i>mmol/l</i>)	< 6.0 <i>mg/dl</i> (below 103 <i>mmol/l</i>)
< 48 hours	< 12.0 <i>mg/dl</i> (below 205 <i>mmol/l</i>)	< 10.0 <i>mg/dl</i> (below 170 <i>mmol/l</i>)
between 3 and 5 days	< 15.0 <i>mg/dl</i> (below 256 <i>mmol/l</i>)	< 12.0 <i>mg/dl</i> (below 205 <i>mmol/l</i>)
7 days and older	< 15.0 <i>mg/dl</i> (below 256 <i>mmol/l</i>)	< 10.0 <i>mg/dl</i> (below 170 <i>mmol/l</i>)

Table 4: Average normal range of bilirubin for neonates [26].

After a preliminary physical examination by a medical practitioner, the diagnosis of jaundice may require bilirubin, liver function and CBC tests [4]. These tests are done more than once in neonates to keep track of altering counts and condition. An elevated bilirubin content in a neonate may resolve itself within a few days to two weeks, and therefore, periodic testing is conducted. For adults, depending on the initial results, additional tests may be conducted. Urinalysis [4], which is an analysis of the urine, is a useful test that may give a fair indication of the presence of bile in urine.

⁵Cholestasis is a condition where the liver cannot successfully secrete bile into a tube-like structure called the bile duct [31].

Similar to anemia, jaundice may be treated by administering blood transfusions or medications [26]. When jaundice occurs in neonates, it can be treated by phototherapy [24]. Phototherapy consists in the use of ultraviolet light to help the neonate’s body to eliminate bilirubin. In certain cases, blockages in and around the liver have to be removed by surgery using a process called ERCP (endoscopic retrograde cholangiopancreatography) [34].

Severe cases of jaundice may result in the failure of important organs such as pancreas, kidneys and liver [35, 36, 13]. They may also lead to certain types of cancer, particularly in older individuals where a blockage in the excretion of bilirubin may result in the formation of a tumor [35]. Among neonates, severe cases of the disease may lead to kernicterus [18], a damage to the central nervous system that may result in death [37].

The measurement of unconjugated bilirubin content, known as serum bilirubin concentration, can be used to determine the jaundice risk levels, notably for neonates [38]. Figure 1 represents the various risk levels associated with varying serum bilirubin concentrations among neonates. Those in the high risk zone may be treated using phototherapy.




Figure 1: A percentile-based predictive bilirubin nomogram, also known as the Bhutani graph [26]. Re-drawn from [26].

When jaundice results from the presence of ductal stones in the bile duct or carcinoma of the head of the pancreas (CAHOP), its treatment may require surgery [39]. Irabor [40] analysed the fall of serum bilirubin contents after operative relief was performed on seven adult patients with this type of obstructive jaundice [40]. The observed pattern of reduction or fall in the bilirubin serum content was that in all seven patients there was an initial precipitous drop of roughly 2/3 of the original value (before operation) by the 2nd post-operative day. There was then a gradual decline up to the 7th post-operative day when the measured contents were one-thirds of the original value. By the 14th day, the serum bilirubin was roughly one-fifths of the original value.

4 Summary

Both anemia and jaundice mainly result from an excessive breakdown of red blood cells at a rate higher than the body can produce. Hemoglobin comprises of 73% of the body's essential iron and thus, best reflects iron status [6]. Women lose more iron in their childbearing years than men. This is primarily because of menstrual blood loss which explains why most studies consider low hemoglobin concentration only in women apart from infants and children. Continual prevalence of anemia can result in jaundice. However, the latter can be a result of other contributing factors as well. Jaundice is observed most commonly among neonates.

While jaundice can be diagnosed in its early stages due to the characteristic yellowish pigmentation of the skin and eyes, anemia can go unnoticed for a long time [41]. It can usually be corrected by suggestive dietary changes or by blood transfusions in severe cases. An exception would be the sickle cell anemia where the red blood cells of a patient are sickle-shaped or crescent-shaped by birth [42].

While much research has been done on studying the causes, effect and treatment of jaundice in neonates, not many studies feature its occurrence in adults. This can be a possible topic for future research which can help us understand the various facets of this condition. Moreover, although several studies talk about severe anemia leading to jaundice [4, 13, 43], to the best of our knowledge, the time frame and stages associated with their interplay are still unknown. As future work, we plan to investigate variations in hemoglobin and bilirubin contents resulting from the simultaneous onset of both conditions.

References

- [1] A. Maton, J. Hopkins, C.W. McLaughlin, S. Johnson, M.Q. Warner, D. LaHart, and J.D. Wright, *Human Biology and Health*, Prentice Hall, 1993.
- [2] E.D.D. de Villota, M.T.R. Carmona, J.J. Rubio, and S. de Andrés, “Equality of the in vivo and in vitro oxygen-binding capacity of haemoglobin in patients with severe respiratory disease,” *British Journal of Anaesthesia*, vol. 53, no. 12, December 1981.
- [3] S. Chang, L. Wang, Y. Wang, I. D. Brouwer, F.J. Kok, and B. Lozoff, “Iron-deficiency anemia in infancy and social emotional development in preschool-aged chinese children,” *Pediatrics*, vol. 127, no. 4, pp. e927–e933, March 2011.
- [4] Department of Health and Human Services, “Anemia: Healthy lifestyle changes, iron deficiency anemia, pernicious anemia, aplastic anemia and hemolytic anemia,” Tech. Rep. 11-7629, National Institutes of Health and National Heart, Lung and Blood Institute, USA, September 2011.
- [5] J. Crawley, “Reducing the Burden of Anemia in Infants and Young Children in Malaria-Endemic Countries of Africa: From Evidence to Action,” *American Society of Tropical Medicine and Hygiene and World Health Organization (WHO)*, vol. 71, no. 2, pp. 25–34, 2004.
- [6] R.O. Earl, C.E. Woteki, and D.H. Calloway, *Iron Deficiency Anemia : Recommended Guidelines for the Prevention, Detection, and Management Among U.S. Children and Women of Childbearing Age*, Food and Nutrition Board, Institute of Medicine, USA, 1993.
- [7] K.M. Van de Graaff, *Human Anatomy*, W.C. Brown Publishers, Dubuque, IO, USA, 4th edition, 1995.
- [8] V. Kumar, “Pernicious anemia,” *MLO Med Labs Obs*, vol. 39, no. 2, February 2007.

- [9] R. Hoffman, E.J. Benz, L.E. Silberstein, H. Heslop, J. Weitz, and J. Anastasi, *Hematology. Basic Principles and Practice*, Number 37. Elsevier Saunders, 6 edition, 2012.
- [10] D.L. Smith, “Anemia in the elderly,” *Am. Fam. Physician*, vol. 62, no. 7, pp. 1565–1572, October 2000.
- [11] “Hemodynamic responses to oxygen breathing in children with severe anemia,” *Circulation*, vol. 40, pp. 493–499, October 1969.
- [12] A. Zeidman, Z. Fradin, A. Blecher, H.S. Oster, Y. Avrahami, and M. Mittelman, “Anemia as a risk factor for ischemic heart disease,” *The Israel Medical Association Journal*, vol. 6, no. 1, pp. 16–18, January 2004.
- [13] J. Fevery, “Bilirubin in clinical practice: a review,” *Liver International*, vol. 28, no. 5, pp. 592–605, May 2008.
- [14] WHO, “Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity,” Geneva, Switzerland, 2011, World Health Organization, pp. 1–6, WHO/NMH/NHD/MnM/11.1.
- [15] D.W. Glaser, “Anemia,” *Case Based Pediatrics For Medical Students and Residents. Department of Pediatrics, University of Hawaii, John A. Burns School of Medicine*, vol. 11, no. 1, February 2002.
- [16] S.G. McGregor and C. Ani, “Iron-deficiency anemia: Reexamining the nature and magnitude of the public health problem, a review of studies on the effect of iron deficiency on cognitive development of children,” *The Journal of Nutrition*, vol. 131, pp. 649–668, 2001.
- [17] B. de Benoist, E. McLean, I. Egli, and M. Cogswell, Eds., *Worldwide prevalence of Anaemia 1993-2005, WHO Global database on Anaemia*, Centers for Disease Control and Prevention, World Health Organization, Atlanta, USA, 2008.
- [18] R. Click, J.D. Smith, L. Fowler, J. DuBose, M.D. Saxton, and J. Herbert, “An osteopathic approach to reduction of readmissions for neonatal jaundice,” *Osteopathic Family Physician*, vol. 5, no. 1, pp. 17–23, January 2013.
- [19] J.E. Hall and A.C. Guyton, *Textbook of Medical Physiology*, 12 edition, 2011.
- [20] D. Pashankar and R.A. Schreiber, “Jaundice in older children and adolescents,” *Pediatrics in Review*, vol. 22, no. 7, pp. 219–226, July 2001.
- [21] H. Miyake, S. Tashiro, S. Yogita, M. Ishikawa, Y. Fukuda, M. Harada, D. Wada, S. Ito, and M. Yasuda, “Can the liver with gilbert’s syndrome be used as graft of living-related liver transplantation?,” *The Journal of Medical Investigation*, vol. 44, no. 3-4, pp. 219–221, February 1998.
- [22] C.P. Strassburg, “Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome),” *Best Practice & Research Clinical Gastroenterology*, vol. 24, no. 5, pp. 555–571, 2010.
- [23] D. Todd, “Thalassemia,” *Pathology*, vol. 16, pp. 5–15, January 1984.
- [24] C.H. Lee, T. Hoang, S. Khan, and L. Ortiz, “Neonatal jaundice - its mathematical model and treatments,” *Rose-Hulman Institute of Technology Undergraduate Math Journal*, vol. 5, no. 1, pp. 1–16, 2004.

- [25] S.D. Zucker, P.S. Horn, and K.E. Sherman, “Serum bilirubin levels in the US population: Gender effect and inverse correlation with colorectal cancer,” *Hepatology*, vol. 40, no. 4, pp. 827–835, October 2004.
- [26] M.J. Maisels, V.K. Bhutani, D. Bogen, T.B. Newman, A.R. Stark, and J.F. Watchko, “Hyperbilirubinemia in the newborn infant 35 weeks’ gestation: An update with clarifications,” *Pediatrics*, vol. 124, no. 4, October 2009.
- [27] R. Keays, “Hepatitis,” *Anaesthesia and intensive care medicine*, vol. 5, no. 8, pp. 283–285, 2004.
- [28] N.C. Vu Lam, P.B. Gotsch, and R.C. Langan, “Caring for pregnant women and newborns with hepatitis B or C,” *Am. Fam. Physician*, vol. 82, no. 10, pp. 1225–1229, November 2010.
- [29] J.M. Torpy, A.E. Burke, and R.M. Golub, “Hepatitis B,” *Journal of the American Medical Association (JAMA)*, vol. 305, no. 14, pp. 1500, April 2011.
- [30] H. Bangura, B. Penner, S. Shaw, V. Steeves, M. Whelan, P. Bélanger, E. Randell, A. Lalani, C. Sanford, F.W. Tremblay, C. Jardine, A. J. Willis, and G. Butler, “Hepatitis c in canada: 2005-2010 surveillance report,” *Centre for Communicable Diseases and Infection Control Infectious Disease Prevention and Control Branch Public Health Agency of Canada*, , no. HP40-70/2012E, 2011.
- [31] K. Allen, H. Jaeschke, and B.L. Copple, “Bile acids induce inflammatory genes in hepatocytes. a novel mechanism of inflammation during obstructive cholestasis,” *The American Journal of Pathology*, vol. 178, no. 1, pp. 175–186, January 2011.
- [32] G.R. Brown and K. Persley, “Hepatitis A epidemic in the elderly,” *Southern Medical Journal*, vol. 95, no. 8, 2002.
- [33] G. Dumitru, A.M. Amariei, and E. Ciornea, “Study of biochemical indices in patients with persistent chronic hepatitis,” *Annals of the ”Alexander Ioan Cuza” University Sect. II A. Genetics and Molecular Biology*, vol. 13, no. 2, pp. 57–62, 2012.
- [34] Department of Health and Human Service, “Ercp (endoscopic retrograde cholangiopancreatography),” Tech. Rep. 12-4336, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, USA, December 2011.
- [35] W.B. McCollum and P.H. Jordan, “Obstructive jaundice in patients with pancreatitis without associated biliary tract disease,” *Annals of Surgery*, vol. 182, no. 2, pp. 116–120, August 1975.
- [36] B.G. Harbrecht, M.R. Rosengart, K. Bukauskas, M.S. Zenati, J.W. Marsh Jr, and D.A. Geller, “Assessment of transcutaneous bilirubinometry in hospitalized adults,” *Journal of the American College of Surgeons*, vol. 206, no. 6, pp. 1129–1136, June 2008.
- [37] W.W. Zuelzer and R.T. Mudgett, “Kernicterus: Etiologic study based on an analysis of 55 cases,” *Pediatrics*, vol. 6, no. 3, pp. 452–474, September 1950.
- [38] R.P. Wennberg, C.E. Ahlfors, V.K. Bhutani, L.H. Johnson, and S.M. Shapiro, “Toward understanding kernicterus: A challenge to improve the management of jaundiced newborns,” *Pediatrics*, vol. 117, no. 2, pp. 474–485, February 2006.

- [39] J. Barkin, D. Vining, A. Miale Jr, S. Gottlieb, D.E. Redlhammer, and M.H. Kaiser, “Computerized tomography, diagnostic ultrasound, and radionuclide scanning. comparison of efficacy in diagnosis of pancreatic carcinoma,” *Journal of the American Medical Association (JAMA)*, vol. 238, no. 19, pp. 2040–2042, November 1977.
- [40] D.O. Irabor, “The pattern of fall of serum bilirubin after operative relief of obstructive jaundice. a preliminary report.,” vol. 7 (2), pp. 8–14, May-August 2009.
- [41] N.L. Gayyed, N. Bouboulis, and M.P. Holden, “Ann. thorac. surg.,” *Open Heart Operationin Patients Suffering from Hereditary Spherocytosis*, vol. 55, 1993.
- [42] Department of Health and Human Services, “A century of progress: Milestones in sickle cell disease research and care,” Tech. Rep. 10-7657, National Institutes of Health and National Heart, Lung and Blood Institute, USA, September 2010.
- [43] R. Carmel, E.T. Wong, J.M. Weiner, and C.S. Johnson, “Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia),” *Journal of the American Medical Association (JAMA)*, vol. 253 (23), pp. 3416–3418, June 1985.